27 May 2022 - The institute recommends platform studies under a master's protocol. ...
19 May 2022 - The Federal Joint Committee (G-BA) has rated the patient-relevant additional benefit of two active ingredients for cancer ...
2 May 2022 - The amendments concern, among other things, the approach to evidence searches for clinical practice guidelines. New ...
19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science. ...
19 April 2022 - There is an indication of a considerable added benefit compared to doxorubicin or paclitaxel. Compared to ...
13 April 2022 - This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to ...
24 March 2022 - Even as prices rose substantially in the U.S. over a recent 12 year period, a new ...
15 March 2022 - Hansa Biopharma completes the AMNOG reimbursement process for Idefirix in Germany. ...
3 March 2022 - A striking example: abemaciclib in advanced breast cancer. Shortened data on quality of life, symptoms and side ...
1 March 2022 - Those affected survive a median of twelve months compared to seven in the control group. Overall, ...
15 February 2022 - Those affected survived a median of 14 months compared to nine in the control group. However, an ...
1 February 2022 - Experience from clinical practice with Zolgensma, a gene therapy against certain forms of spinal muscular atrophy in ...
24 January 2022 - The innovations concern, among other things, the procedure for evidence searches for medical guidelines. New concept ...
20 January 2022 - The Federal Joint Committee (G-BA) today exempted three drugs classified as reserve antibiotics from the regular early ...
20 January 2022 - The Federal Joint Committee (G-BA) today classified the additional benefit of the active ingredient blinatumomab as significant ...